BioCardia
Overview
Products
Case Reports
Publications & Talks
Patents
Press & News
Scientific Advisors

Press Releases

BioCardia, Inc. releases the MorphTM 6 French Deflectable Guide Catheter

South San Francisco, CA., May 12, 2005

BioCardia, Inc. has released the Morph TM 6 French Universal Deflectable Guide Catheter. This latest Morph product family member is based on state-of-the-art catheter technology that provides the ability to change shape to navigate within anatomy.

“The Morph TM enables personalizing the guide catheter geometry to the patients' anatomy and the disease presentation”, says BioCardia CEO, Peter Altman . “We believe this makes for a safer and speedier intervention for the surgeon and patient. The Morph™ product line is already becoming important for treating serious vascular disease where precision and control for local device and therapeutic intervention are important.”

Morph TM catheters are based on micro machined nitinol shaft technology to provide control and precision. BioCardia's 8 French Morph™ product has been used with success in more than 500 cases in: renal arteries, AAA graft implantations, iliac artery, femoral artery, celiac artery, superior mesenteric arteries, lumbar artery coiling, coronary arteries, cardiac chambers, carotid arteries access, and other applications. The safety record with this device is stellar, and BioCardia continues to be vigilant with respect to quality and physician service to maintain this record.

The 6 French Morph™ expands the deflectable guide catheter technology into a size suitable for interventional cardiology. It behaves nearly identically to the 8 French device, but has the advantages of being significantly smaller and being compatible with a significantly smaller sheath introducer. The new 6 French device has a 4 French inner lumen size and its distal tip can be curved up to 180 degrees by the physician during a procedure.

BioCardia believes we are doing great things for advancing patient care, while also building a strong business based on fundamentals.

About BioCardia
Formed in 1999, BioCardia, Inc. is a leader in the development of catheter systems which enable local delivery of therapeutics to the heart and other organs. BioCardia currently is marketing the BioCardia Morph™ Deflectable Tip Guide Catheter and the company’s main focus continues to be in the developing field of biointerventional cardiology with emphasis on locally delivered agents. Biotherapeutic clinical trials are ongoing using BioCardia’s Helical Infusion System to deliver cell, gene, and protein therapies directly to the heart muscle.

For more information, contact: Investor Relations, BioCardia, Inc. 650-624-0900, .